NOXXON, Secures

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX) (Paris:ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today an expansion of the agreement with Atlas Special Opportunities, LLC (ASO) for the additional provision of up to €17 million in equity-linked securities.

29.12.2021 - 18:02:31

NOXXON Secures €17 Million Expansion of Equity-Linked Facility with Atlas to Advance NOX-A12 in Glioblastoma and Pancreatic Cancer Programs. Additionally, today, NOXXON issued 2,419 convertible bonds (including 44 convertible bonds issued in relation to the transaction fee) for a total of €2.419 million nominal value.

and Twitter.

About the GLORIA Study

GLORIA (NCT04121455) is NOXXON’s dose-escalation, phase 1/2 study of NOX-A12 in combination with irradiation in first-line glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy).

About the OPTIMUS Study

OPTIMUS (NCT04901741) is NOXXON’s open-label two-arm phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

ANNEX

Table: Dilutive Potential of Convertible Bond Vehicle assuming conversion price of €0.27 per share

 

Description

Price per
share paid

No. Bonds
Converted

Shares
Received

Nominal Value
Converted to
Shares*

Dilution

Shareholder
starting with
1% would then
hold **

Middle Tranche existing vehicle

€ 0.27

475

1,759,259

€ 475,000

6.60%

0.93%

New Tranche of

EUR 1 million

€ 0.27

1,000

3,703,703

€ 1,000,000

12.95%

0.87%

All 17 New Tranches

€ 0.27

17,000

62,962,962

€ 17,000,000

71.67%

0.28%

Conversion of all remaining uncalled tranches and 17 New Tranches

€ 0.27

27,450

101,666,666

€ 27,450,000

80.33%

0.20%

* Rounded up for simplicity of presentation for amounts not used due to fractional shares.

** The percentages shown each take into consideration only the dilutive effect of the transaction(s) specified in the Description column of the same row; these percentages are not cumulative with above rows.

 

@ businesswire.com